Welcome to our dedicated page for OS THERAPIES INCORPORATED SEC filings (Ticker: OSTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The OS Therapies Incorporated (OSTX) SEC filings page on Stock Titan brings together the company’s official disclosures to the U.S. Securities and Exchange Commission, offering a primary source view of its clinical-stage oncology business. As a NYSE American–listed emerging growth company, OS Therapies uses current reports on Form 8-K, registration statements, and proxy materials to describe its listeria-based cancer immunotherapy programs, ADC and drug conjugate platform, capital structure, and governance decisions.
Investors can use this page to access Form 8-K filings that detail material events such as warrant exercise inducement and exchange offers, gross proceeds from warrant exercises, and the terms of new warrants issued to accredited investors. These filings explain how OS Therapies raises capital to support regulatory submissions and commercial preparation for its lead asset OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma and to fund preparations for the proposed spin-off of its veterinary subsidiary, OS Animal Health.
Other 8-Ks and the company’s definitive proxy statement on Schedule 14A provide insight into corporate governance, including amendments to the certificate of incorporation to increase authorized common stock, changes to the 2023 Incentive Compensation Plan, quorum requirements under the bylaws, and shareholder approvals related to potential share issuances and a shareholder rights agreement. Registration statements on Form S-1 and Form S-3 describe the resale of shares underlying warrants, the company’s status as a smaller reporting company and emerging growth company, and the use of proceeds from warrant exercises.
Through Stock Titan, these filings are updated in near real time from EDGAR and are paired with AI-powered summaries that translate legal and financial language into plain English. Users can quickly understand the key points of complex documents, such as how a warrant inducement affects dilution, what changes a bylaw amendment introduces, or how a registration statement relates to existing warrants. Over time, this filings archive helps investors follow OS Therapies’ progress as it advances OST-HER2 through the regulatory process, develops its tunable ADC (tADC) platform, and executes on planned transactions like the OS Animal Health spin-off.
OS Therapies Inc director reports stock option grant. A director of OS Therapies Inc (OSTX) reported receiving stock options to purchase 140,000 shares of the company’s common stock on October 21, 2025, at an exercise price of $1.80 per share. The options vest in full on the one-year anniversary of the grant date, as long as the director is still serving on the board at that time, and are scheduled to expire on October 21, 2035.
OS Therapies Inc. director receives new stock option grant. A reporting person serving as a director of OS Therapies Inc. (ticker OSTX) was granted stock options on October 21, 2025 to purchase 140,000 shares of the company’s common stock at an exercise price of $1.8 per share. These options vest in full on the one-year anniversary of the grant date, as long as the individual continues to serve as a director on that date, and are scheduled to expire on October 21, 2035. Following this grant, the director beneficially owns 140,000 stock options directly.
OS Therapies Inc director reports new stock option grant and holdings. On October 21, 2025, director John Ciccio was granted stock options to buy 140,000 shares of OS Therapies Inc common stock at an exercise price of $1.8 per share. These options vest in full on the one-year anniversary of the grant date, if he is still serving as a director on that date, and expire on October 21, 2035.
After the reported transactions, he beneficially owns 435,835 shares of common stock indirectly through Mill River Partners LLC and 20,000 shares directly, in addition to the 140,000 stock options held directly.
OS Therapies Inc. reported that its Chief Financial Officer received a new stock option grant. On October 21, 2025, the reporting person was granted options to purchase 200,000 shares of OS Therapies common stock at an exercise price of $1.8 per share, under a stock option award agreement.
The options vest in full on the one-year anniversary of the grant date, as long as the individual is still serving as an employee on that date. Following this grant, the reporting person holds 109,375 shares of common stock directly and 200,000 stock options directly.
OS Therapies Inc director Avril McKean-Dieser reported new equity awards and current holdings. As of the reported transactions, the director beneficially owns 5,000 shares of OS Therapies common stock in direct ownership. On October 21, 2025, the director was granted stock options to purchase 140,000 shares of common stock at an exercise price of $1.8 per share. These options vest in full on the one-year anniversary of the grant date, provided the director is still serving on the board at that time, and expire on October 21, 2035. The grant reflects part of the director’s equity-based compensation.
OS Therapies (OSTX) filed its quarterly report for the period ended September 30, 2025. The company reported a net loss of $6.9 million for the quarter and $15.3 million year‑to‑date, driven by higher research and development ($7.6 million YTD) and general and administrative expenses ($9.2 million YTD). Cash was $1.88 million, and management stated these conditions raise “substantial doubt” about the company’s ability to continue as a going concern.
Total assets rose to $9.0 million, reflecting the April acquisition of HER2 immuno‑oncology assets from Ayala, recorded at a fair value of $6.86 million, largely paid in common stock. The company recognized $236 thousand of amortization on these intangibles year‑to‑date. Stockholders’ equity improved to $3.64 million from a deficit at year‑end 2024, aided by conversions of preferred stock and warrant activity.
Operating cash burn was $10.5 million YTD, partly offset by $7.3 million in financing cash inflows, including warrant exercises and a preferred stock raise. The warrant liability declined to $0 with a $1.42 million favorable fair value change. Shares outstanding were 35,214,352 as of November 14, 2025.
OS Therapies (OSTX) reported results of its 2025 annual meeting and stockholders approved an amendment to the company’s 2023 Incentive Compensation Plan. The meeting was held on October 21, 2025, with 20,516,482 shares present in person or by proxy out of 31,998,288 shares entitled to vote, establishing a quorum.
Votes were recorded on director nominees and other proposals as detailed, and the amended plan text was filed as Exhibit 10.1. Routine meeting items, including proposals receiving broker non-votes, were also tallied.
OS Therapies (OSTX) filed an 8-K announcing two items. First, the company furnished an investor presentation, available on its website and attached as Exhibit 99.1.
Second, the company adjourned its 2025 annual meeting held on October 14, 2025, to allow additional time to solicit proxies. The meeting will reconvene at 10:00 a.m. Eastern time on October 21, 2025, in a virtual format at https://meeting.vstocktransfer.com/OSTHERAPIESOCT25. Based on the preliminary tabulation of votes received, the Issuance Proposal, the Charter Amendment Proposal and the Auditor Ratification Proposal received the requisite votes for approval. The record date remains August 20, 2025. Stockholders of record who have not voted are encouraged to do so by October 20, 2025 at 11:59 p.m. Eastern time. Proxies previously submitted will be voted at the reconvened meeting unless properly revoked.
OS Therapies Incorporated filed a Form 8-K describing a new prospectus supplement that is part of its effective Form S-3 shelf registration. The prospectus supplement covers the resale from time to time of up to 4,373,043 shares of OS Therapies common stock by selling stockholders named in the supplement.
The company used this report to provide investors with the legal opinion from its counsel, Olshan Frome Wolosky LLP, on the validity of these shares, which is filed as Exhibit 5.1, along with the related consent and the cover page interactive data file.
OS Therapies, Inc. (OSTX) prospectus supplement and base prospectus materials include disclosures about securities that may be offered, methods of distribution, and governance and capital-structure terms. The filing references the company’s Annual Report for year ended December 31, 2024 (filed March 31, 2025) and Quarterly Reports for periods ended March 31, 2025 and June 30, 2025 (filed May 15, 2025 and August 18, 2025), together with a series of Current Reports filed on specified 2025 dates. The prospectus outlines features of potential offerings of common stock, debt securities, warrants, rights, units and Series A senior convertible preferred stock, including conversion triggers (qualified public offering >$10.0 million at ≥$12.00/share; qualified PIPE >$20.0 million at ≥$12.00/share; third‑party cash acquisition at ≥$12.00/share; or sustained VWAP test), a 150% liquidation preference on Series A senior convertible preferred, and voting and conversion mechanics (one vote per share, as-converted voting subject to a $3.78 voting price floor). The document also lists permitted distribution methods, investor protections and typical indenture events of default and trustee procedures. It discloses certain scaled reporting exemptions available to smaller reporting companies.